[1]帅苍南,张玉亭,刘 敏,等.抗慢性乙型肝炎肝纤维化中成药研究进展[J].医学信息,2022,35(08):38-42.[doi:10.3969/j.issn.1006-1959.2022.08.010]
 SHUAI Cang-nan,ZHANG Yu-ting,LIU Min,et al.Research Progress of Anti-chronic Hepatitis B Liver Fibrosis Chinese Patent Medicine[J].Medical Information,2022,35(08):38-42.[doi:10.3969/j.issn.1006-1959.2022.08.010]
点击复制

抗慢性乙型肝炎肝纤维化中成药研究进展()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年08期
页码:
38-42
栏目:
综述
出版日期:
2022-04-15

文章信息/Info

Title:
Research Progress of Anti-chronic Hepatitis B Liver Fibrosis Chinese Patent Medicine
文章编号:
1006-1959(2022)08-0038-05
作者:
帅苍南张玉亭刘 敏
(1.云南中医药大学第一临床医学院,云南 昆明 650000;2.云南省第一人民医院感染性疾病及肝病科,云南 昆明 650000)
Author(s):
SHUAI Cang-nanZHANG Yu-tingLIU Minet al.
(1.First Clinical Medical College,Yunnan University of Chinese Medicine,Kunming 650000,Yunnan,China;2.Department of Infectious Diseases and Liver Diseases,the First People’s Hospital of Yunnan Province,Kunming 650000,Yunnan,China)
关键词:
肝纤维化乙型肝炎病毒慢性乙型肝炎中医药
Keywords:
Liver fibrosisHepatitis B virusChronic hepatitis BTraditional Chinese medicine
分类号:
R256.4
DOI:
10.3969/j.issn.1006-1959.2022.08.010
文献标志码:
A
摘要:
肝纤维化指的是肝脏细胞外基质的弥漫性过度沉积和异常分布。在我国,慢性乙型肝炎是导致肝纤维化的主要原因。乙肝肝纤维化可进一步进展为肝硬化和肝癌。中医药在治疗乙肝及肝纤维化方面具有显著优势。本文就近年中医药抗肝纤维化的相关研究进行综述。
Abstract:
Hepatic fibrosis refers to the diffuse excessive deposition and abnormal distribution of liver extracellular matrix. In China, chronic hepatitis B is the main cause of liver fibrosis. Hepatitis B liver fibrosis can further progress to cirrhosis and liver cancer. Traditional Chinese medicine has obvious advantages in the treatment of hepatitis B and liver fibrosis. This paper reviews the related research on anti-hepatic fibrosis of traditional Chinese medicine in recent years.

参考文献/References:

[1]Bataller R,Brenner DA.Liver fibrosis[J].J Clin Invest,2005,115(2):209-218.[2]Lo RC,Kim H.Histopathological evaluation of liver fibrosis and cirrhosis regression[J].Clin Mol Hepatol,2017,23(4):302-307.[3]Kim SU,Oh HJ,Wanless IR,et al.The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis[J].J Hepatol,2012,57(3):556-563.[4]Zhang L,Schuppan D.Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype[J].J Hepatol,2014,61(1):166-168.[5]中华医学会肝病学分会.肝硬化诊治指南[J].临床肝胆病杂志,2019,35(11):2408-2425.[6]Marcellin P,Gane E,Buti M,et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J].Lancet,2013(381):468-475.[7]Weiskirchen R.Hepatoprotective and anti-fibrotic agents: it’s time to take the next step[J].Front Pharmacol,2016(6):303.[8]Tacke F,Weiskirchen R.An update on the recent advances in antifibrotic therapy[J].Expert Rev Gastroenterol Hepatol,2018(12):1143-1152.[9]北京中医医院.关幼波临床经验选[M].北京:人民卫生出版社,2006:130-141.[10]叶放,薛博瑜,周珉,等.论湿热瘀毒与肝纤维化[J].南京中医药大学学报(自然科学版),2005,21(6):346-349.[11]王灵台,陈建杰,高月求,等.补肾法为主治疗慢性肝病的临床研究[J].中医药通报,2005,4(2):26-31.[12]中华中医药学会肝胆病专业委员会,中国民族医药学会肝病专业委员会.慢性乙型肝炎中医诊疗指南(2018年版)[J].临床肝胆病杂志,2018,34(12):2520-2525. [13]徐列明,刘平,沈锡中,等.肝纤维化中西医结合诊疗指南(2019年版)[J].临床肝胆病杂志,2019,35(7):1444-1449.[14]王凤云,唐旭东,刘燕玲,等.慢性乙型肝炎患者中医证型特点及分布差异[J].世界华人消化杂志,2008(7):716-720.[15]高风琴,徐慧媛,李筠.慢性乙型肝炎病理诊断与中医证型关系初探[J].北京中医药,2010,29(7):525-526.[16]杨婵娟,刘宏伟,王丽春,等.慢性乙型肝炎肝郁脾虚证和脾胃湿热证患者的差异表达基因研究初探[J].中国中西医结合杂志,2012,32(8):1032-1037.[17]Liu X,Wan T,Dang S,et al.HLA-DQB1/DRB1 Alleles Associate with Traditional Chinese Medicine Syndrome of Chronic Hepatitis B: A Potential Predictor of Progression[J].Biomed Res Int,2019(2019):8146937.[18]Shi MJ,Xiao HM,Xie YB,et al.Differences in MicroRNA Expression in Chronic Hepatitis B Patients with Early Liver Fibrosis Based on Traditional Chinese Medicine Syndromes[J].Evid Based Complement Alternat Med,2020(2020):5956940.[19]Liu Y,Liu P,Dai R,et al.Analysis of plasma proteome from cases of the different traditional Chinese medicine syndromes in patients with chronic hepatitis B[J].J Pharm Biomed Anal,2012(59):173-178.[20]Xie HP,Liu ZP,Zhang JS,et al.Traditional Chinese Medicine Syndrome Patterns and Their Association with Hepatitis B Surface Antigen Levels during the Natural History of Chronic Hepatitis B Virus Infection[J].Evid Based Complement Alternat Med,2018(2018):7482593.[21]李厚钢.鳖甲抗肝纤维化的物质基础研究[D].武汉:湖北中医药大学,2020.[22]高世乐,胡宗涛,董六一.赤芍总苷对大鼠放射性肝纤维化的保护作用及机制[J].中药药理与临床,2012,28(2):66-69.[23]王宪波,刘平,唐志鹏,等.冬虫夏草菌丝提取物降低二甲基亚硝胺大鼠肝硬化门静脉高压效应的组织学基础[J].中西医结合学报,2008,6(11):1136-1144.[24]方士英,徐茂红,叶良兵,等.冬虫夏草对免疫性肝损伤小鼠模型的保护作用研究[J].中国免疫学杂志,2011,27(10):891-894.[25]吴建良,王志勇,孙丽伟,等.虫草菌丝对肝纤维化小鼠肝脏脂质过氧化的影响[J].中国药师,2012,15(3):381-384.[26]周光德,李文淑,赵景民,等.复方鳖甲软肝片抗肝纤维化机制的临床病理研究[J].解放军医学杂志,2004,29(7):563-564.[27]袁强,何岚,陈芝芸,等.复方鳖甲软肝片对肝纤维化大鼠肝脏血管紧张素Ⅱ及其受体mRNA表达的影响[J].中华中医药杂志,2008,23(2):158-161.[28]赵景民,周光德,李文淑,等.复方鳖甲软肝片抗肝纤维化机制的实验研究[J].解放军医学杂志,2004(7):560-562.[29]Rong G,Chen Y,Yu Z,et al.Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients With Chronic Hepatitis B Treated With Entecavir: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial[J].J Infect Dis,2022,225(6):1091-1099. [30]石小枫,徐曼,刘杞.三七总皂甙对肝纤维化大鼠Ⅰ、Ⅲ型胶原及TGF-β1的影响[J].中药药理与临床,2001,17(2):7-8.[31]李校天,杨书良,王军民,等.水蛭对Ang-Ⅱ刺激鼠肝星状细胞活化Ca2+效应的抑制作用[J].中国全科医学,2006(6):472-474.[32]贾彦,牛英才,张英博,等.水蛭素对大鼠纤维化肝组织Smad4 mRNA表达的影响[J].陕西中医,2009,30(1):119-121.[33]王丹,杨玲,黄金明,等.牛磺熊去氧胆酸抑制四氯化碳诱导的大鼠肝纤维化[J].世界华人消化杂志,2010,18(19):1979-1984.[34]王林,卢玮,高玉华,等.安络化纤丸对肝纤维化大鼠肝组织基质金属蛋白酶及其抑制物表达的影响[J].中华肝脏病杂志,2019,27(4):267-273.[35]王统华,周喜汉,何守搞,等.安络化纤丸辅助治疗对乙型肝炎肝硬化患者血清炎性因子、肝纤维化指标及免疫功能的影响[J].海南医学院学报,2017,23(16):2184-2187,2191.[36]苗亮,杨婉娜,董晓琴,等.安络化纤丸联合恩替卡韦治疗可显著提高慢性乙型肝炎病毒感染者肝纤维化的改善率[J].中华肝脏病杂志,2019,27(7):521-526.[37]张彩华,李骢,李华军,等.丹参酮ⅡA干预肝纤维化模型大鼠相关信号通路相关因子的表达[J].中国组织工程研究,2015,(27):4345-4350.[38]魏国微,李克跃.丹参酮ⅡA对血管紧张素Ⅱ诱导的大鼠肝星状细胞TGF-β1/Smads通路的影响[J].贵阳中医学院学报,2016,38(2):36-40.[39]Chen J,Hu Y,Chen L,et al.The effect and mechanisms of Fuzheng Huayu formula against chronic liver diseases[J].Biomed Pharmacother,2019(114):108846.[40]Gui HL,Zhao CQ,Wang Y,et al.Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis[J].J Clin Transl Hepatol,2020,8(3):277-284.[41]Andrade RJ,Medina-Caliz I,Gonzalez-Jimenez A,et al.Hepatic Damage by Natural Remedies[J].Semin Liver Dis,2018,38(1):21-40.[42]肖小河,李秀惠,朱云,等.中草药相关肝损伤临床诊疗指南[J].临床肝胆病杂志,2016,32(5):835-843.[43]Itoh S,Marutani K,Nishijima T,et al.Liver injuries induced by herbal medicine,syo-saiko-to (xiao-chai-hu-tang)[J].Dig Dis Sci,1995,40(8):1845-1848.[44]Hsu LM,Huang YS,Tsay SH,et al.Acute hepatitis induced by Chinese hepatoprotective herb,xiao-chai-hu-tang[J].J Chin Med Assoc,2006,69(2):86-88.[45]Shimada Y,Fujimoto M,Nogami T,et al.Recurrent Drug-induced Liver Injury Caused by the Incidental Readministration of a Kampo Formula Containing Scutellariae Radix[J].Intern Med,2018,57(12):1733-1740.[46]Enomoto Y,Nakamura Y,Enomoto N,et al.Japanese herbal medicine-induced pneumonitis: A review of 73 patients[J].Respir Investig,2017,55(2):138-144.[47]Kamiyama T,Nouchi T,Kojima S,et al.Autoimmune hepatitis triggered by administration of an herbal medicine[J].Am J Gastroenterol,1997(92):703-704.[48]Katou K,Mori K.Autoimmune hepatitis with drug-induced pneumonia due to Sho-saiko-to[J].Nihon Kokyuki Gakkai Zasshi,1999(37):641-646.[49]Kiguchi T,Kimura F,Niiya K,et al.Acute thrombocytopenic purpura after ingestion of Sho-saiko-to for hepatitis[J].Liver,2000(20):491.

相似文献/References:

[1]王艳欣,孟庆华,朱跃科.非侵入性检查方法评价肝纤维化的研究进展[J].医学信息,2018,31(03):40.[doi:10.3969/j.issn.1006-1959.2018.03.014]
 WANG Yan-xin,MENG Qing-hua,ZHU Yue-ke.Progress in Evaluation of Liver Fibrosis by Non-invasive Methods[J].Medical Information,2018,31(08):40.[doi:10.3969/j.issn.1006-1959.2018.03.014]
[2]李顶春,李 武.Wnt信号通路与肝纤维化[J].医学信息,2018,31(09):4.[doi:10.3969/j.issn.1006-1959.2018.09.002]
 LI Ding-chun,LI Wu.Wnt Signaling Pathway and Hepatic Fibrosis[J].Medical Information,2018,31(08):4.[doi:10.3969/j.issn.1006-1959.2018.09.002]
[3]艾迎春,迟男男,杜景峰,等.芪参二莲汤对肝纤维化大鼠基质金属蛋白酶-1及 抑制因子的影响[J].医学信息,2018,31(15):140.[doi:10.3969/j.issn.1006-1959.2018.15.045]
 AI Ying-chun,CHI Nan-nan,DU Jing-feng,et al.Effects of Qishenerlian Decoction on Matrix Metalloproteinase-1 and Its Inhibitory Factors in Rats with Hepatic Fibrosis[J].Medical Information,2018,31(08):140.[doi:10.3969/j.issn.1006-1959.2018.15.045]
[4]钱熠辉,彭 琼.乙型肝炎病毒感染与结直肠腺瘤的相关性研究[J].医学信息,2019,32(04):81.[doi:10.3969/j.issn.1006-1959.2019.04.027]
 QIAN Yi-hui,PENG Qiong.Correlation between Hepatitis B Virus Infection and Colorectal Adenoma[J].Medical Information,2019,32(08):81.[doi:10.3969/j.issn.1006-1959.2019.04.027]
[5]杨美玲,黄荷凤.HBV暴露对子代影响的研究进展[J].医学信息,2019,32(10):32.[doi:10.3969/j.issn.1006-1959.2019.10.012]
 YANG Mei-ling,HUANG He-feng.Advances in Research on the Effects of HBV Exposure on Offspring[J].Medical Information,2019,32(08):32.[doi:10.3969/j.issn.1006-1959.2019.10.012]
[6]董 朴,蔡福景,张 东,等.胆维他片对肝纤维化大鼠肝中抗氧化体系的影响[J].医学信息,2019,32(18):138.[doi:10.3969/j.issn.1006-1959.2019.18.046]
 DONG Pu,CAI Fu-jing,ZHANG Dong,et al.Effect of Danweiita Tablet on Antioxidant System in Liver of Rats with Hepatic Fibrosis[J].Medical Information,2019,32(08):138.[doi:10.3969/j.issn.1006-1959.2019.18.046]
[7]林思萍,龚先琼.中药单体调控TGF-β1/Smads信号通路抗纤维化的研究[J].医学信息,2019,32(21):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
 LIN Si-ping,GONG Xian-qiong.Study on Anti-Fibrosis of TGF-β1/Smads Signaling Pathway Regulated by Chinese Medicine Monomer[J].Medical Information,2019,32(08):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
[8]唐细田,肖 琳,徐彤慧.化学发光法和酶联免疫法在乙型肝炎病毒血清学检验中的效果比较[J].医学信息,2019,32(22):164.[doi:10.3969/j.issn.1006-1959.2019.22.057]
 TANG Xi-tian,XIAO Lin,XU Tong-hui.Comparison of the Effects of Chemiluminescence and Enzyme-linked Immunosorbent Assay on Serological Test of Hepatitis B Virus[J].Medical Information,2019,32(08):164.[doi:10.3969/j.issn.1006-1959.2019.22.057]
[9]张小雨,严 艳.自身免疫性肝炎合并自身免疫性疾病的特征研究[J].医学信息,2020,33(02):89.[doi:10.3969/j.issn.1006-1959.2020.02.024]
 ZHANG Xiao-yu,YAN Yan.Study on the Characteristics of Autoimmune Hepatitis Combined with Autoimmune Diseases[J].Medical Information,2020,33(08):89.[doi:10.3969/j.issn.1006-1959.2020.02.024]
[10]苏振华.乙肝病毒标记物阳性表型血清标本乙型肝炎病毒HBV-DNA临床检验分析[J].医学信息,2020,33(04):179.[doi:10.3969/j.issn.1006-1959.2020.04.061]
 SU Zhen-hua.Clinical Analysis of Hepatitis B Virus HBV-DNA in Serum Specimen with Hepatitis B Virus Markers Positive[J].Medical Information,2020,33(08):179.[doi:10.3969/j.issn.1006-1959.2020.04.061]

更新日期/Last Update: 1900-01-01